首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease.
【24h】

Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease.

机译:在非糖尿病性肾脏疾病中,ace抑制剂的抗蛋白尿作用无法及时逃脱。

获取原文
获取原文并翻译 | 示例
           

摘要

Angiotensin-converting enzyme (ACE) inhibitors exert a renoprotective effect in both diabetic and nondiabetic renal disease with variable efficacy. Proteinuric patients with nondiabetic renal disease, normotension, and restricted protein and sodium intake were treated with ACE inhibitors without diuretics. Fifty-nine patients were treated with either lisinopril (10 mg/d; 36 patients) or enalapril (5 mg/d; 23 patients) over a period of 37.7 +/- 20.7 months. Urinary protein excretion decreased to less than 50% of pretreatment values after 1 to 37 months (6.9 +/- 8.8 months) of therapy in 33 patients (56%); in 29 patients, it reached less than 0.5 g/d of protein. Urinary protein levels remained low in 19 of the 33 patients (57.5%) throughout the entire posttreatment period (30.8 +/- 17.7 months). However, in the remaining 14 patients, escape from the antiproteinuric effect was detected after 19.2 +/- 13.4 months, evidenced by a decrease in the rate of change in creatinine clearance from 0.052 +/- 0.114 mL/min/mon during the low-proteinuria period to -0.697 +/- 1.101 mL/min/mon after the lapse of antiproteinuric effect (P: < 0.001). Although ACE inhibitors reduce the severity of proteinuria in patients with nondiabetic renal disease, our results show that a proportion of patients escape the antiproteinuric effect and subsequently develop an exacerbation of renal dysfunction.
机译:血管紧张素转换酶(ACE)抑制剂在糖尿病和非糖尿病性肾脏疾病中均具有肾脏保护作用,且疗效不一。患有非糖尿病性肾脏疾病,血压正常,蛋白质和钠摄入受限的蛋白尿患者使用不含利尿剂的ACE抑制剂治疗。在37.7 +/- 20.7个月的时间内,对59例患者进行了赖诺普利(10 mg / d; 36例患者)或依那普利(5 mg / d; 23例患者)的治疗。 33例患者(56%)在治疗1至37个月(6.9 +/- 8.8个月)后,尿蛋白排泄降低至治疗前值的50%以下;在29位患者中,其蛋白质含量低于0.5 g / d。在整个治疗后期间(30.8 +/- 17.7个月)中,33例患者中的19例(57.5%)的尿蛋白水平仍然很低。但是,其余14例患者在19.2 +/- 13.4个月后发现未从抗蛋白尿作用中逃脱,这表明肌酐清除率的变化率从低水平期间的0.052 +/- 0.114 mL / min / mon降低。抗蛋白尿作用失效后,蛋白尿期降至-0.697 +/- 1.101 mL / min / mon(P:<0.001)。尽管ACE抑制剂可降低非糖尿病肾病患者蛋白尿的严重程度,但我们的研究结果表明,一部分患者摆脱了抗蛋白尿作用,并随后加剧了肾功能不全。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号